The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Brussels meeting: Advancing personalised treatment for childhood AML across Europe

NOPHO-DB-SHIP consortium at last year's meeting in Utrecht, NL. Photo: Private
The NOPHO-DB-SHIP consortium at last year's meeting in Utrecht, NL. Photo: Private

In May, pediatric cancer experts from 16 countries gathered in Brussels for the annual meeting of the NOPHO-DB-SHIP consortium—an EU-wide collaboration working to improve outcomes for children with Acute Myeloid Leukemia (AML). In Sweden, the trial is coordinated by Lund University and Skåne University Hospital.

At the center of this collaboration is the CHIP-AML22 trial—an international phase III study targeting newly diagnosed AML in patients aged 0–18. Sponsored by the Princess Máxima Center (Netherlands) and supported by the EU4Health programme through HaDEA, the trial is coordinated in Sweden by Lund University and Skåne University Hospital, with additional support from national organizations like the Swedish Childhood Cancer Fund (Barncancerfonden).

“Since we obtained financial support from the EU (HaDEA – European Health and Digital Executive Agency), we decided to hold this year’s physical meeting close to the EU, in Brussels. Also, for that reason, we held a public session during our meeting where we invited EU representatives to participate, as well as, for instance, funding organizations and patient representative organisations. From Sweden, the Childhood Cancer Fund and Lund University participated”, says Kees-Jan Pronk, international vice-PI for the study, researcher at Lund University and head of pediatric oncology at Skåne University Hospital.

What is CHIP-AML22?
CHIP-AML22 aims to improve treatment efficacy by evaluating the addition of targeted treatment (Gemtuzumab) to a chemotherapy backbone, while at the same time reducing treatment toxicity by omitting one of three consolidation chemotherapy blocks”, says Kees-Jan Pronk.

The trial also serves as a platform for linked early-phase studies focused on specific genetic subtypes of AML, including an upcoming trial with Quizartinib for patients with FLT3-ITD mutations.

All six Swedish childhood cancer centers are now enrolling patients, with more than half of the 55 participating international sites already open. Full activation is expected in 2025, marking a major step toward personalized pediatric AML treatment in Europe—and beyond.

Childhood AML: Progress and future directions

Questions and answers with Kees-Jan Pronk. 

How come survival rates have improved for children with AML?
One major reason is that we've become better at identifying which children need more aggressive treatment and which do not. This progress is largely due to two key advances:

  • Genetic testing – We now use more detailed genetic tests to better understand the specific type of AML each child has.
  • Monitoring treatment response – We've improved our ability to detect whether treatment is working by using advanced tests like flow cytometry and molecular MRD (measurable residual disease) analysis, which can find even tiny amounts of remaining cancer cells.

Are there other factors contributing to better outcomes?
Yes. Supportive care during treatment has also significantly improved. We’re now better at managing side effects and complications caused by both the disease and the treatment. This enables us to safely deliver the intensive therapy needed to treat AML.

What are the current challenges in AML treatment?
Although survival has improved, AML treatment is already very intensive, and adding more traditional chemotherapy isn’t always feasible because it can be too harsh on the body.

What is the future direction for AML treatment in children?
We need new, targeted treatments—drugs that specifically attack cancer cells without harming healthy ones. Some of these treatments have already shown promise, particularly in children or adults with relapsed AML. In the coming years, researchers, including us, will study whether giving these drugs from the very beginning can help prevent relapse and save even more lives.

Contact

Portrait Kees-Jan Pronk. Photo.

Kees-Jan Pronk, international vice-PI CHIP-AML22, researcher at Lund University and head of pediatric oncology at Skåne University Hospital

Profile in Lund University's research profile

NOPHO-DB-SHIP consortium

Nordic Society Pediatric Hematology Oncology includes following member countries: Sweden Denmark, Finland, Norway, Iceland, Latvia, Estonia and Lithuania, as well as the Netherlands, Belgium, Hong Kong, Spain, Israel and Portugal. Switzerland and Uruguay have expressed their interest to join the consortium.

CHIP-AML22

Childhood International Protocol – Acute Myeloid Leukaemia 2022 (CHIP-AML22) treats children up to the age of 18 year old with newly diagnosed AML.

Visit the project website

HaDEA/EU4Health

EU4Health is the fourth and largest of the EU health programmes since their launch in 2003. The EU4Health project will aid to implement diagnostic procedures and treatment modalities in CHIP-AML22 in all participating countries within the EU.

Vist HaDEA/EU4Health website